The OPTIONS study was described as a double-blind, placebo-controlled trial in 502 adults with obesity who received oral AOD9604 or placebo once daily for 24 weeks together with a diet-and-exercise program
What is the biggest mistake patients make when starting GLP-1 therapy? Escalating dose too quickly
A visit is also helpful if you have type 2 diabetes, rising A1C, weight-related health risks, high blood pressure, high cholesterol, or confusion about GLP-1 medications
This combination is used to explore multi-pathway peptide signalling, molecular binding dynamics and cellular response patterns within preclinical research environments
Interested in taking part in a GLP-1 clinical trial
As with any wellness change, results vary from person to person